Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients |
Type de publication | Journal Article |
Year of Publication | 2019 |
Auteurs | Chelle P, Montmartin A, Damien P, Piot M, Cournil M, Lienhart A, Genre-Volot F, Chambost H, Morin C, Tardy-Poncet B |
Journal | HAEMOPHILIA |
Volume | 25 |
Pagination | 343-348 |
Date Published | MAR |
Type of Article | Article |
ISSN | 1351-8216 |
Mots-clés | Coagulation, haemophilia, multiple linear regression, thrombin generation, tissue factor pathway inhibitor |
Résumé | The thrombin generation (TG) assay evaluates haemostatic balance, which is influenced by the levels of many coagulation factors and inhibitors. Our objective was to identify the determinant factors of TG in haemophilia A (HA) and haemophilia B (HB) patients and to compare them to those in healthy controls. Coagulation factor and inhibitor levels, and TG, were measured in platelet-poor plasma from 40 patients with HA, 32 patients with HB and 40 healthy subjects. Data were analysed using multiple regression models. In HA patients, factor VIII was a positive determinant of endogenous thrombin potential (ETP) and peak, whereas tissue factor pathway inhibitor (TFPI) and factor V were negative determinants of ETP and peak. In HB patients, FIX was a positive determinant of ETP and peak, FVII being a positive determinant of peak. Antithrombin and protein S (PS) were negative determinants of ETP while FX was a negative determinant of peak. Above all, in HB patients, TFPI was a negative determinant of ETP and peak. In healthy subjects, FVIII was a positive determinant of ETP and peak, whereas FX and protein S were negative determinants of these parameters. TFPI was not a negative determinant of either peak or ETP. In haemophilic patients, the determinant factors of TG are all implicated in FXa generation and inhibition, the crucial determinant factor being TFPI whatever the type of haemophilia, A or B. These findings contribute to the rationale that recently place TFPI as a target for innovative therapies of haemophilia. |
DOI | 10.1111/hae.13679 |